Introduction {#sec1-1}
============

Ectopical meningiomas (extracranial meningiomas) are extremely rare: despite being one of the most frequently diagnosed primary intracranial tumors, meningioma rarely occurs in several locations such as the head-and-neck region, skin, bone, peripheral nerves, retroperitoneum, and lung.\[[@ref1][@ref2]\] Different histogenetic and pathologic mechanisms have been proposed, but the true etiology of this tumor is still uncertain:\[[@ref3]\] Some authors believe that extracranial meningioma might derive from misplaced or migrate arachnoid cells, other investigators have revealed that the tumor may originate from perineurial cells or pluripotent mesenchymal cells.\[[@ref2]\]

The first reported case of primary pulmonary meningioma (PPM) was in 1982.\[[@ref4]\] To the best of our knowledge, till date, only 44 cases have been reported in the literature: among these cases, only five were malignant or atypical.\[[@ref1][@ref2]\]

Case Report {#sec1-2}
===========

An 80-year-old male, from whom we obtain the consent form, during the follow-up for thymoma (previous thymectomy in 2011) and kidney cancer (previous nephrectomy in 2012), presented a solitary pulmonary nodule in the superior lobe of the right lung as detectable by means of ^18^F fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) scan in December 2015 (injected dose 380 MBq). PET/CT images showed a metabolically active lesion (SUVmax 4.63 g/ml bw, 14 mm in diameter), suspected of being a metastasis \[[Figure 1](#F1){ref-type="fig"}\]. Contrast-enhanced CT with iodinated contrast media performed after PET examination did not show significant attenuation between pre- and postcontrast phase \[[Figure 2](#F2){ref-type="fig"}\]. After a right pulmonary resection in January 2016, bioptic diagnosis of the nodule was compatible with fibrotic (benign) pulmonary meningioma.

![Positron emission tomography/computed tomography image of the fibrous (benign) pulmonary meningioma](IJNM-34-45-g001){#F1}

![Contrast-enhanced computed tomography image of the fibrous (benign) pulmonary meningioma](IJNM-34-45-g002){#F2}

In June 2016, another ^18^F FDG PET/CT scan was performed in the same patient (injected dose 361 MBq) that showed another new metabolically active pseudonodular lesion (SUVmax 2.46 g/ml bw, 12 mm in diameter) in the superior lobe of the left lung \[[Figure 3](#F3){ref-type="fig"}\]. A CT scan with iodinated contrast, the lesion showed enhancement at postcontrast phase \[basal scan:-1 HU; postcontrast scan: 55 HU, [Figure 4](#F4){ref-type="fig"}\]. After an atypical resection of the superior lobe of the left lung in September 2016, biopsy showed a high proliferative activity with a number of mitotic figures \>20/10 HPF, Ki-67 ≈ 20%, with associated necrosis and on immunohistochemistry cells expressed epithelial membrane antigen and they were positive for vimentin and progesterone: the final diagnosis was anaplastic meningioma (malignant).

![Positron emission tomography/computed tomography image of the malignant pulmonary meningioma](IJNM-34-45-g003){#F3}

![Contrast-enhanced computed tomography image of malignant pulmonary meningioma](IJNM-34-45-g004){#F4}

Discussion {#sec1-3}
==========

To the best of our knowledge, this is the first ^18^F FDG PET/CT evaluation of a patient with synchronous benign and malignant PPM, with similar dimensions (14 and 12 mm in diameter): qualitative and semi-quantitative (SUVmax) analysis with PET suggested less metabolic activity in malignant PPM, with more intense uptake of ^18^F FDG in fibrotic PPM. Furthermore, anaplastic meningioma showed enhancement with iodinated contrast media. From this case report, we conclude that ^18^F FDG PET may not suffice in the evaluations of patients with PPM; the conjunction with contrast-enhanced CT may help in the discrimination between malign and benign lesions. Furthermore, due to high levels of expression of the somatostatin receptor subtype 2 in meningiomas, the use of other radiolabeled compounds (i.e., ^68^Ga-DOTATOC PET/CT\[[@ref1][@ref5]\]) may be more useful for this aim.
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